BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24516522)

  • 21. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
    Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
    Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
    J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of [
    Tovmassian D; Abdul Razak M; London K
    Int J Surg Oncol; 2016; 2016():6162182. PubMed ID: 28058117
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential clinical role of FDG-PET in detecting sarcomatous transformation in von Recklinghausen's disease: a case study and review of the literature.
    Basu S; Nair N
    J Neurooncol; 2006 Oct; 80(1):91-5. PubMed ID: 16850110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J; Mautner VF; Adam G; Derlin T
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report.
    Otsuka H; Graham MM; Kubo A; Nishitani H
    Ann Nucl Med; 2005 Feb; 19(1):55-8. PubMed ID: 15770975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors.
    Broski SM; Johnson GB; Howe BM; Nathan MA; Wenger DE; Spinner RJ; Amrami KK
    Skeletal Radiol; 2016 Aug; 45(8):1097-105. PubMed ID: 27115884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can 18F-FDG PET/CT diagnose malignant change in benign chondroid tumors?
    Purandare NC; Puranik A; Shah S; Agrawal A; Puri A; Gulia A; Nayak P; Rekhi B; Rangarajan V
    Nucl Med Commun; 2019 Jun; 40(6):645-651. PubMed ID: 30921251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
    Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of 18F-FDG PET/computed tomography in prognostication and management of malignant peripheral nerve sheath tumors.
    Yadav D; Shamim SA; Rastogi S; Upadhyay DMR; Pandey AK; Kumar R
    Nucl Med Commun; 2020 Sep; 41(9):924-932. PubMed ID: 32796481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
    Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
    Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.
    Cardona S; Schwarzbach M; Hinz U; Dimitrakopoulou-Strauss A; Attigah N; Mechtersheimer section sign G; Lehnert T
    Eur J Surg Oncol; 2003 Aug; 29(6):536-41. PubMed ID: 12875862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.
    Brenner W; Friedrich RE; Gawad KA; Hagel C; von Deimling A; de Wit M; Buchert R; Clausen M; Mautner VF
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):428-32. PubMed ID: 16404595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.